OBJECTIVES: The Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) assesses the impact of RLS on daily life, emotional well-being, social life, and work life. This study investigates its validity and reliability. METHODS: The RLSQoL was tested in 85 American adults with primary RLS. Patients were also asked to rate symptom severity with the International Restless Legs Scale (patient-reported version) and report on changes in symptoms over the 2-week period. RESULTS: The RLSQoL summary scale score (range: 0-100) demonstrated acceptable internal consistency reliability (Cronbach's alpha = 0.92) and test-retest reliability (intraclass correlation coefficient = 0.84). All items indicated acceptable item-convergent validity. The RLSQoL distinguished between groups with mild, moderate, and severe symptoms (F = 52.22, P < 0.0001). It demonstrated preliminary responsiveness to changes in RLS status over 2 weeks (effect size: improvement, 0.25; deterioration, -0.32), indicating moderate scale changes consistent with the small clinical change over this time. CONCLUSIONS: These findings support the conceptual framework of the RLSQoL. It is a valid and reliable measure of the impact of RLS on QoL and is responsive to short-term changes in symptom severity. The RLSQoL appears to be an appropriate tool for trial-based assessments of treatments for RLS.
OBJECTIVES: The Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) assesses the impact of RLS on daily life, emotional well-being, social life, and work life. This study investigates its validity and reliability. METHODS: The RLSQoL was tested in 85 American adults with primary RLS. Patients were also asked to rate symptom severity with the International Restless Legs Scale (patient-reported version) and report on changes in symptoms over the 2-week period. RESULTS: The RLSQoL summary scale score (range: 0-100) demonstrated acceptable internal consistency reliability (Cronbach's alpha = 0.92) and test-retest reliability (intraclass correlation coefficient = 0.84). All items indicated acceptable item-convergent validity. The RLSQoL distinguished between groups with mild, moderate, and severe symptoms (F = 52.22, P < 0.0001). It demonstrated preliminary responsiveness to changes in RLS status over 2 weeks (effect size: improvement, 0.25; deterioration, -0.32), indicating moderate scale changes consistent with the small clinical change over this time. CONCLUSIONS: These findings support the conceptual framework of the RLSQoL. It is a valid and reliable measure of the impact of RLS on QoL and is responsive to short-term changes in symptom severity. The RLSQoL appears to be an appropriate tool for trial-based assessments of treatments for RLS.
Authors: Arthur S Walters; Birgit Frauscher; Richard Allen; Heike Benes; K Ray Chaudhuri; Diego Garcia-Borreguero; Hochang B Lee; Daniel L Picchietti; Claudia Trenkwalder; Pablo Martinez-Martin; Glenn T Stebbins; Anette Schrag Journal: J Clin Sleep Med Date: 2014-12-15 Impact factor: 4.062
Authors: Rose A Franco; Ramesh Ashwathnarayan; Arshana Deshpandee; Joshua Knox; Jack Daniel; Daniel Eastwood; Jose Franco; Kia Saeian Journal: J Clin Sleep Med Date: 2008-02-15 Impact factor: 4.062
Authors: Diego Garcia-Borreguero; Jeffrey Patrick; Sarah DuBrava; Philip M Becker; Alan Lankford; Crystal Chen; Jeffrey Miceli; Lloyd Knapp; Richard P Allen Journal: Sleep Date: 2014-04-01 Impact factor: 5.849